Share Price and Basic Stock Data
Last Updated: February 1, 2026, 9:24 pm
| PEG Ratio | -1.43 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Sanofi India Ltd, a prominent player in the pharmaceuticals industry, reported a share price of ₹4,078 and a market capitalization of ₹9,379 Cr. The company’s sales for the financial year ending December 2023 stood at ₹1,996 Cr, marking a decline from ₹2,770 Cr in December 2022. This downward trend in sales reflects broader challenges within the sector, as evidenced by fluctuating quarterly sales figures, which peaked at ₹736 Cr in March 2023 but dropped to ₹469 Cr by December 2023. The trailing twelve months (TTM) revenue was ₹1,932 Cr, indicating a need for strategic adjustments to counteract declining sales. Notably, the company’s operational profit margin (OPM) was 24% in December 2023, showing a slight decrease from 25% in December 2022. These revenue trends highlight the volatility in the pharmaceutical market and the necessity for Sanofi India to innovate and adapt to market demands effectively.
Profitability and Efficiency Metrics
Sanofi India Ltd’s profitability metrics demonstrate a mixed performance. The net profit for December 2023 was reported at ₹603 Cr, a decrease from ₹621 Cr in December 2022. The earnings per share (EPS) stood at ₹262.26 for December 2023, down from ₹269.83 the previous year. However, the return on equity (ROE) was remarkably high at 47.2%, indicating effective utilization of shareholder funds, while the return on capital employed (ROCE) reached 49.2%, reflecting strong operational efficiency. The company maintained an impressive interest coverage ratio (ICR) of 338.20x, suggesting robust ability to meet interest obligations. Sanofi’s operational efficiency is further evidenced by a cash conversion cycle (CCC) of 77 days, indicating a relatively efficient management of working capital. These metrics highlight the company’s strong profitability potential, albeit tempered by recent declines in net income.
Balance Sheet Strength and Financial Ratios
Sanofi India Ltd’s balance sheet reflects significant strength, with total assets reported at ₹1,612 Cr as of December 2024. The company maintains a conservative borrowing strategy, with borrowings amounting to ₹21 Cr, which is low compared to its reserves of ₹759 Cr. This results in a debt-to-equity ratio that is favorable, supporting financial stability. The price-to-book value (P/BV) ratio stood at 16.36x, indicating that the market values the company significantly higher than its book value, which can be indicative of strong growth expectations. However, the current ratio of 1.57x suggests a potential liquidity concern, as it is slightly below the ideal threshold of 2. The overall financial ratios reflect a company that is well-positioned, though it must remain vigilant about maintaining liquidity as it navigates a changing market landscape.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Sanofi India Ltd shows a stable structure, with promoters holding 60.40% of the equity, signifying strong insider confidence in the company. Foreign institutional investors (FIIs) held 5.57%, while domestic institutional investors (DIIs) accounted for 22.28% of the shareholding, indicating a healthy interest from institutional investors. The public held 11.75%, reflecting a diversified ownership base. Notably, the number of shareholders increased to 71,395 by September 2025, which could suggest growing retail interest. However, the gradual decline in FII participation from 6.99% in December 2022 to 5.57% in September 2025 might raise concerns about foreign investor sentiment. This mixed ownership landscape points to a resilient company, yet it must address any potential issues that could deter foreign investment.
Outlook, Risks, and Final Insight
Looking ahead, Sanofi India Ltd faces both opportunities and challenges. The pharmaceutical sector is poised for growth due to increasing healthcare demands, but the company must navigate a competitive landscape where innovation is critical. Risks include the declining sales trend and potential impacts from regulatory changes, which could affect profitability. If Sanofi can leverage its strong ROE and ROCE, it may enhance its product offerings and operational efficiency. However, failure to address sales decline could jeopardize investor confidence, particularly among FIIs. The company’s robust balance sheet provides a cushion against short-term volatility, allowing it to invest in strategic initiatives. Overall, Sanofi India Ltd stands at a crossroads, where strategic decisions made in the coming periods will significantly influence its trajectory in the pharmaceutical market.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 119 Cr. | 94.7 | 195/84.3 | 26.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,538 Cr. | 325 | 479/192 | 73.3 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.8 Cr. | 46.9 | 82.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 71.8 Cr. | 49.0 | 49.7/17.0 | 171 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,449.33 Cr | 1,087.86 | 46.53 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 692 | 672 | 736 | 515 | 491 | 469 | 511 | 464 | 524 | 515 | 536 | 406 | 475 |
| Expenses | 510 | 505 | 507 | 393 | 377 | 370 | 374 | 348 | 404 | 397 | 364 | 311 | 341 |
| Operating Profit | 182 | 167 | 230 | 122 | 114 | 100 | 137 | 116 | 120 | 118 | 172 | 95 | 134 |
| OPM % | 26% | 25% | 31% | 24% | 23% | 21% | 27% | 25% | 23% | 23% | 32% | 23% | 28% |
| Other Income | 11 | 34 | 44 | 57 | 82 | 77 | 41 | 21 | 2 | 14 | 3 | 9 | -22 |
| Interest | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 9 | 9 |
| Profit before tax | 182 | 190 | 264 | 169 | 186 | 167 | 169 | 127 | 113 | 122 | 165 | 94 | 102 |
| Tax % | 28% | 31% | 28% | 27% | 18% | 18% | 19% | 19% | 27% | 25% | 28% | 26% | 26% |
| Net Profit | 131 | 131 | 190 | 123 | 152 | 138 | 137 | 103 | 82 | 91 | 120 | 70 | 76 |
| EPS in Rs | 56.91 | 56.91 | 82.78 | 53.43 | 66.17 | 59.87 | 59.39 | 44.96 | 35.74 | 39.70 | 51.96 | 30.22 | 33.04 |
Last Updated: December 29, 2025, 6:33 am
Below is a detailed analysis of the quarterly data for Sanofi India Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 475.00 Cr.. The value appears strong and on an upward trend. It has increased from 406.00 Cr. (Jun 2025) to 475.00 Cr., marking an increase of 69.00 Cr..
- For Expenses, as of Sep 2025, the value is 341.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 311.00 Cr. (Jun 2025) to 341.00 Cr., marking an increase of 30.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 134.00 Cr.. The value appears strong and on an upward trend. It has increased from 95.00 Cr. (Jun 2025) to 134.00 Cr., marking an increase of 39.00 Cr..
- For OPM %, as of Sep 2025, the value is 28.00%. The value appears strong and on an upward trend. It has increased from 23.00% (Jun 2025) to 28.00%, marking an increase of 5.00%.
- For Other Income, as of Sep 2025, the value is -22.00 Cr.. The value appears to be declining and may need further review. It has decreased from 9.00 Cr. (Jun 2025) to -22.00 Cr., marking a decrease of 31.00 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 9.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 102.00 Cr.. The value appears strong and on an upward trend. It has increased from 94.00 Cr. (Jun 2025) to 102.00 Cr., marking an increase of 8.00 Cr..
- For Tax %, as of Sep 2025, the value is 26.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 26.00%.
- For Net Profit, as of Sep 2025, the value is 76.00 Cr.. The value appears strong and on an upward trend. It has increased from 70.00 Cr. (Jun 2025) to 76.00 Cr., marking an increase of 6.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 33.04. The value appears strong and on an upward trend. It has increased from 30.22 (Jun 2025) to 33.04, marking an increase of 2.82.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:41 am
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,809 | 1,977 | 2,193 | 2,367 | 2,460 | 2,771 | 3,071 | 2,902 | 2,957 | 2,770 | 1,996 | 2,013 | 1,932 |
| Expenses | 1,411 | 1,639 | 1,817 | 1,832 | 1,921 | 2,146 | 2,403 | 2,186 | 2,194 | 2,066 | 1,508 | 1,522 | 1,413 |
| Operating Profit | 398 | 339 | 376 | 535 | 538 | 625 | 667 | 716 | 762 | 704 | 488 | 491 | 519 |
| OPM % | 22% | 17% | 17% | 23% | 22% | 23% | 22% | 25% | 26% | 25% | 24% | 24% | 27% |
| Other Income | 83 | 131 | 218 | 66 | 79 | 88 | 33 | 45 | 564 | 204 | 318 | 79 | 4 |
| Interest | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 92 | 97 | 113 | 119 | 102 | 103 | 100 | 82 | 67 | 42 | 36 | 37 | 37 |
| Profit before tax | 388 | 373 | 481 | 480 | 515 | 610 | 600 | 677 | 1,258 | 864 | 767 | 531 | 484 |
| Tax % | 32% | 29% | 33% | 37% | 37% | 38% | 31% | 29% | 25% | 28% | 21% | 22% | |
| Net Profit | 265 | 264 | 322 | 304 | 326 | 381 | 414 | 478 | 944 | 621 | 603 | 414 | 356 |
| EPS in Rs | 115.30 | 114.61 | 139.78 | 132.26 | 141.74 | 165.48 | 180.09 | 207.65 | 410.61 | 269.83 | 262.26 | 179.78 | 154.92 |
| Dividend Payout % | 39% | 39% | 46% | 51% | 50% | 51% | 194% | 176% | 119% | 211% | 64% | 65% |
YoY Net Profit Growth
| Year |
|---|
| YoY Net Profit Growth (%) |
| Change in YoY Net Profit Growth (%) |
No data available for trend analysis.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -8% |
| 3 Years: | -12% |
| TTM: | 2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 0% |
| 3 Years: | -9% |
| TTM: | 1% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 0% |
| 3 Years: | 11% |
| 1 Year: | -31% |
| Return on Equity | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | 32% |
| 3 Years: | 41% |
| Last Year: | 47% |
Last Updated: September 5, 2025, 1:25 pm
Balance Sheet
Last Updated: August 11, 2025, 2:43 pm
| Month | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 |
| Reserves | 1,324 | 1,463 | 1,604 | 1,860 | 2,003 | 2,196 | 2,419 | 2,096 | 2,203 | 1,253 | 992 | 838 | 759 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 23 | 25 | 24 | 19 | 19 | 21 |
| Other Liabilities | 532 | 742 | 778 | 658 | 751 | 765 | 802 | 777 | 811 | 772 | 681 | 732 | 436 |
| Total Liabilities | 1,878 | 2,228 | 2,405 | 2,541 | 2,778 | 2,984 | 3,244 | 2,918 | 3,061 | 2,072 | 1,715 | 1,612 | 1,239 |
| Fixed Assets | 699 | 648 | 877 | 817 | 769 | 733 | 499 | 464 | 334 | 306 | 315 | 312 | 309 |
| CWIP | 136 | 210 | 22 | 34 | 30 | 21 | 17 | 10 | 13 | 24 | 16 | 18 | 16 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Other Assets | 1,043 | 1,369 | 1,505 | 1,690 | 1,978 | 2,230 | 2,728 | 2,444 | 2,714 | 1,743 | 1,382 | 1,281 | 914 |
| Total Assets | 1,878 | 2,228 | 2,405 | 2,541 | 2,778 | 2,984 | 3,244 | 2,918 | 3,061 | 2,072 | 1,715 | 1,612 | 1,239 |
Below is a detailed analysis of the balance sheet data for Sanofi India Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Equity Capital, as of Jun 2025, the value is 23.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 23.00 Cr..
- For Reserves, as of Jun 2025, the value is 759.00 Cr.. The value appears to be declining and may need further review. It has decreased from 838.00 Cr. (Dec 2024) to 759.00 Cr., marking a decrease of 79.00 Cr..
- For Borrowings, as of Jun 2025, the value is 21.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 19.00 Cr. (Dec 2024) to 21.00 Cr., marking an increase of 2.00 Cr..
- For Other Liabilities, as of Jun 2025, the value is 436.00 Cr.. The value appears to be improving (decreasing). It has decreased from 732.00 Cr. (Dec 2024) to 436.00 Cr., marking a decrease of 296.00 Cr..
- For Total Liabilities, as of Jun 2025, the value is 1,239.00 Cr.. The value appears to be improving (decreasing). It has decreased from 1,612.00 Cr. (Dec 2024) to 1,239.00 Cr., marking a decrease of 373.00 Cr..
- For Fixed Assets, as of Jun 2025, the value is 309.00 Cr.. The value appears to be declining and may need further review. It has decreased from 312.00 Cr. (Dec 2024) to 309.00 Cr., marking a decrease of 3.00 Cr..
- For CWIP, as of Jun 2025, the value is 16.00 Cr.. The value appears to be declining and may need further review. It has decreased from 18.00 Cr. (Dec 2024) to 16.00 Cr., marking a decrease of 2.00 Cr..
- For Investments, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00 Cr..
- For Other Assets, as of Jun 2025, the value is 914.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,281.00 Cr. (Dec 2024) to 914.00 Cr., marking a decrease of 367.00 Cr..
- For Total Assets, as of Jun 2025, the value is 1,239.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,612.00 Cr. (Dec 2024) to 1,239.00 Cr., marking a decrease of 373.00 Cr..
Notably, the Reserves (759.00 Cr.) exceed the Borrowings (21.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 398.00 | 339.00 | 376.00 | 535.00 | 538.00 | 625.00 | 667.00 | 693.00 | 737.00 | 680.00 | 469.00 | 472.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 24 | 21 | 24 | 22 | 29 | 21 | 27 | 19 | 18 | 17 | 24 | 42 |
| Inventory Days | 151 | 179 | 173 | 169 | 151 | 154 | 127 | 107 | 110 | 125 | 254 | 186 |
| Days Payable | 83 | 122 | 81 | 79 | 119 | 110 | 100 | 93 | 105 | 109 | 112 | 151 |
| Cash Conversion Cycle | 92 | 78 | 115 | 112 | 61 | 65 | 54 | 33 | 22 | 33 | 167 | 77 |
| Working Capital Days | 43 | 26 | 9 | 79 | 17 | 18 | 35 | -8 | -20 | -19 | 35 | 20 |
| ROCE % | 29% | 22% | 26% | 27% | 26% | 29% | 28% | 32% | 35% | 41% | 44% | 49% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Contra Fund | 251,576 | 0.21 | 102.82 | 161,000 | 2025-12-07 15:45:16 | 56.26% |
| Aditya Birla Sun Life Large Cap Fund | 250,365 | 0.33 | 102.33 | N/A | N/A | N/A |
| Nippon India Pharma Fund | 230,272 | 1.14 | 94.12 | 236,008 | 2025-12-08 04:19:42 | -2.43% |
| Nippon India Growth Mid Cap Fund | 226,766 | 0.22 | 92.68 | N/A | N/A | N/A |
| Nippon India Small Cap Fund | 213,992 | 0.13 | 87.46 | 196,342 | 2025-12-08 07:42:13 | 8.99% |
| Nippon India Multi Cap Fund | 152,371 | 0.12 | 62.28 | 152,371 | 2025-04-22 17:25:21 | 0% |
| SBI ELSS Tax Saver Fund | 147,988 | 0.19 | 60.49 | N/A | N/A | N/A |
| SBI Midcap Fund | 128,577 | 0.23 | 52.55 | 195,082 | 2026-01-26 05:01:22 | -34.09% |
| Aditya Birla Sun Life Balanced Advantage Fund | 81,404 | 0.37 | 33.27 | N/A | N/A | N/A |
| Aditya Birla Sun Life Consumption Fund | 75,252 | 0.47 | 30.76 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Dec 24 | Dec 23 |
|---|---|---|
| FaceValue | 10.00 | 10.00 |
| Basic EPS (Rs.) | 179.46 | 261.78 |
| Diluted EPS (Rs.) | 179.46 | 261.78 |
| Cash EPS (Rs.) | 195.65 | 279.35 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 374.17 | 441.39 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 374.17 | 441.39 |
| Revenue From Operations / Share (Rs.) | 875.30 | 1239.61 |
| PBDIT / Share (Rs.) | 220.57 | 377.83 |
| PBIT / Share (Rs.) | 204.61 | 360.61 |
| PBT / Share (Rs.) | 187.57 | 367.61 |
| Net Profit / Share (Rs.) | 179.69 | 262.13 |
| NP After MI And SOA / Share (Rs.) | 179.69 | 262.13 |
| PBDIT Margin (%) | 25.19 | 30.47 |
| PBIT Margin (%) | 23.37 | 29.09 |
| PBT Margin (%) | 21.42 | 29.65 |
| Net Profit Margin (%) | 20.52 | 21.14 |
| NP After MI And SOA Margin (%) | 20.52 | 21.14 |
| Return on Networth / Equity (%) | 48.02 | 59.38 |
| Return on Capital Employeed (%) | 52.72 | 77.98 |
| Return On Assets (%) | 25.64 | 35.15 |
| Asset Turnover Ratio (%) | 1.21 | 0.00 |
| Current Ratio (X) | 1.57 | 1.92 |
| Quick Ratio (X) | 0.87 | 0.89 |
| Inventory Turnover Ratio (X) | 0.60 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 139.85 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 131.23 |
| Earning Retention Ratio (%) | 0.00 | -39.85 |
| Cash Earning Retention Ratio (%) | 0.00 | -31.23 |
| Interest Coverage Ratio (X) | 338.20 | 511.18 |
| Interest Coverage Ratio (Post Tax) (X) | 235.27 | 345.18 |
| Enterprise Value (Cr.) | 13783.39 | 18147.83 |
| EV / Net Operating Revenue (X) | 6.85 | 6.37 |
| EV / EBITDA (X) | 27.17 | 20.88 |
| MarketCap / Net Operating Revenue (X) | 6.99 | 6.51 |
| Retention Ratios (%) | 0.00 | -39.85 |
| Price / BV (X) | 16.36 | 18.28 |
| Price / Net Operating Revenue (X) | 6.99 | 6.51 |
| EarningsYield | 0.02 | 0.03 |
After reviewing the key financial ratios for Sanofi India Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Dec 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Dec 23) which recorded 10.00.
- For Basic EPS (Rs.), as of Dec 24, the value is 179.46. This value is within the healthy range. It has decreased from 261.78 (Dec 23) to 179.46, marking a decrease of 82.32.
- For Diluted EPS (Rs.), as of Dec 24, the value is 179.46. This value is within the healthy range. It has decreased from 261.78 (Dec 23) to 179.46, marking a decrease of 82.32.
- For Cash EPS (Rs.), as of Dec 24, the value is 195.65. This value is within the healthy range. It has decreased from 279.35 (Dec 23) to 195.65, marking a decrease of 83.70.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Dec 24, the value is 374.17. It has decreased from 441.39 (Dec 23) to 374.17, marking a decrease of 67.22.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Dec 24, the value is 374.17. It has decreased from 441.39 (Dec 23) to 374.17, marking a decrease of 67.22.
- For Revenue From Operations / Share (Rs.), as of Dec 24, the value is 875.30. It has decreased from 1,239.61 (Dec 23) to 875.30, marking a decrease of 364.31.
- For PBDIT / Share (Rs.), as of Dec 24, the value is 220.57. This value is within the healthy range. It has decreased from 377.83 (Dec 23) to 220.57, marking a decrease of 157.26.
- For PBIT / Share (Rs.), as of Dec 24, the value is 204.61. This value is within the healthy range. It has decreased from 360.61 (Dec 23) to 204.61, marking a decrease of 156.00.
- For PBT / Share (Rs.), as of Dec 24, the value is 187.57. This value is within the healthy range. It has decreased from 367.61 (Dec 23) to 187.57, marking a decrease of 180.04.
- For Net Profit / Share (Rs.), as of Dec 24, the value is 179.69. This value is within the healthy range. It has decreased from 262.13 (Dec 23) to 179.69, marking a decrease of 82.44.
- For NP After MI And SOA / Share (Rs.), as of Dec 24, the value is 179.69. This value is within the healthy range. It has decreased from 262.13 (Dec 23) to 179.69, marking a decrease of 82.44.
- For PBDIT Margin (%), as of Dec 24, the value is 25.19. This value is within the healthy range. It has decreased from 30.47 (Dec 23) to 25.19, marking a decrease of 5.28.
- For PBIT Margin (%), as of Dec 24, the value is 23.37. This value exceeds the healthy maximum of 20. It has decreased from 29.09 (Dec 23) to 23.37, marking a decrease of 5.72.
- For PBT Margin (%), as of Dec 24, the value is 21.42. This value is within the healthy range. It has decreased from 29.65 (Dec 23) to 21.42, marking a decrease of 8.23.
- For Net Profit Margin (%), as of Dec 24, the value is 20.52. This value exceeds the healthy maximum of 10. It has decreased from 21.14 (Dec 23) to 20.52, marking a decrease of 0.62.
- For NP After MI And SOA Margin (%), as of Dec 24, the value is 20.52. This value exceeds the healthy maximum of 20. It has decreased from 21.14 (Dec 23) to 20.52, marking a decrease of 0.62.
- For Return on Networth / Equity (%), as of Dec 24, the value is 48.02. This value is within the healthy range. It has decreased from 59.38 (Dec 23) to 48.02, marking a decrease of 11.36.
- For Return on Capital Employeed (%), as of Dec 24, the value is 52.72. This value is within the healthy range. It has decreased from 77.98 (Dec 23) to 52.72, marking a decrease of 25.26.
- For Return On Assets (%), as of Dec 24, the value is 25.64. This value is within the healthy range. It has decreased from 35.15 (Dec 23) to 25.64, marking a decrease of 9.51.
- For Asset Turnover Ratio (%), as of Dec 24, the value is 1.21. It has increased from 0.00 (Dec 23) to 1.21, marking an increase of 1.21.
- For Current Ratio (X), as of Dec 24, the value is 1.57. This value is within the healthy range. It has decreased from 1.92 (Dec 23) to 1.57, marking a decrease of 0.35.
- For Quick Ratio (X), as of Dec 24, the value is 0.87. This value is below the healthy minimum of 1. It has decreased from 0.89 (Dec 23) to 0.87, marking a decrease of 0.02.
- For Inventory Turnover Ratio (X), as of Dec 24, the value is 0.60. This value is below the healthy minimum of 4. It has increased from 0.00 (Dec 23) to 0.60, marking an increase of 0.60.
- For Dividend Payout Ratio (NP) (%), as of Dec 24, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 139.85 (Dec 23) to 0.00, marking a decrease of 139.85.
- For Dividend Payout Ratio (CP) (%), as of Dec 24, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 131.23 (Dec 23) to 0.00, marking a decrease of 131.23.
- For Earning Retention Ratio (%), as of Dec 24, the value is 0.00. This value is below the healthy minimum of 40. It has increased from -39.85 (Dec 23) to 0.00, marking an increase of 39.85.
- For Cash Earning Retention Ratio (%), as of Dec 24, the value is 0.00. This value is below the healthy minimum of 40. It has increased from -31.23 (Dec 23) to 0.00, marking an increase of 31.23.
- For Interest Coverage Ratio (X), as of Dec 24, the value is 338.20. This value is within the healthy range. It has decreased from 511.18 (Dec 23) to 338.20, marking a decrease of 172.98.
- For Interest Coverage Ratio (Post Tax) (X), as of Dec 24, the value is 235.27. This value is within the healthy range. It has decreased from 345.18 (Dec 23) to 235.27, marking a decrease of 109.91.
- For Enterprise Value (Cr.), as of Dec 24, the value is 13,783.39. It has decreased from 18,147.83 (Dec 23) to 13,783.39, marking a decrease of 4,364.44.
- For EV / Net Operating Revenue (X), as of Dec 24, the value is 6.85. This value exceeds the healthy maximum of 3. It has increased from 6.37 (Dec 23) to 6.85, marking an increase of 0.48.
- For EV / EBITDA (X), as of Dec 24, the value is 27.17. This value exceeds the healthy maximum of 15. It has increased from 20.88 (Dec 23) to 27.17, marking an increase of 6.29.
- For MarketCap / Net Operating Revenue (X), as of Dec 24, the value is 6.99. This value exceeds the healthy maximum of 3. It has increased from 6.51 (Dec 23) to 6.99, marking an increase of 0.48.
- For Retention Ratios (%), as of Dec 24, the value is 0.00. This value is below the healthy minimum of 30. It has increased from -39.85 (Dec 23) to 0.00, marking an increase of 39.85.
- For Price / BV (X), as of Dec 24, the value is 16.36. This value exceeds the healthy maximum of 3. It has decreased from 18.28 (Dec 23) to 16.36, marking a decrease of 1.92.
- For Price / Net Operating Revenue (X), as of Dec 24, the value is 6.99. This value exceeds the healthy maximum of 3. It has increased from 6.51 (Dec 23) to 6.99, marking an increase of 0.48.
- For EarningsYield, as of Dec 24, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Dec 23) to 0.02, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Sanofi India Ltd:
- Net Profit Margin: 20.52%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 52.72% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 48.02% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 235.27
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.87
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 25.4 (Industry average Stock P/E: 46.53)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 20.52%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Sanofi House, Mumbai Maharashtra 400072 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Aditya Narayan | Chairman & Ind.Director |
| Mr. Rodolfo Hrosz | Managing Director |
| Mr. Rachid Ayari | WholeTime Director & CFO |
| Ms. Renee Amonkar | Whole Time Director |
| Mr. Vaibhav Karandikar | Non Executive Director |
| Mrs. Usha Thorat | Independent Director |
| Mr. Rahul Bhatnagar | Independent Director |
FAQ
What is the intrinsic value of Sanofi India Ltd?
Sanofi India Ltd's intrinsic value (as of 02 February 2026) is ₹2760.65 which is 32.07% lower the current market price of ₹4,064.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹9,360 Cr. market cap, FY2025-2026 high/low of ₹6,718/3,976, reserves of ₹759 Cr, and liabilities of ₹1,239 Cr.
What is the Market Cap of Sanofi India Ltd?
The Market Cap of Sanofi India Ltd is 9,360 Cr..
What is the current Stock Price of Sanofi India Ltd as on 02 February 2026?
The current stock price of Sanofi India Ltd as on 02 February 2026 is ₹4,064.
What is the High / Low of Sanofi India Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Sanofi India Ltd stocks is ₹6,718/3,976.
What is the Stock P/E of Sanofi India Ltd?
The Stock P/E of Sanofi India Ltd is 25.4.
What is the Book Value of Sanofi India Ltd?
The Book Value of Sanofi India Ltd is 340.
What is the Dividend Yield of Sanofi India Ltd?
The Dividend Yield of Sanofi India Ltd is 2.88 %.
What is the ROCE of Sanofi India Ltd?
The ROCE of Sanofi India Ltd is 49.2 %.
What is the ROE of Sanofi India Ltd?
The ROE of Sanofi India Ltd is 47.2 %.
What is the Face Value of Sanofi India Ltd?
The Face Value of Sanofi India Ltd is 10.0.